An interventional study of Dietary Supplement - Placebo and Geranylgeraniol (150 mg) in Muscle Health, Muscle Strength and Body Composition, sponsored by Lindenwood University. Recruiting at 1 site in United States. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Lindenwood University · Not applicable, Interventional, and Basic science
This study will evaluate the effects of daily geranylgeraniol (GG) supplementation on muscular strength, body composition, and aerobic capacity in healthy, physically active men and women. Approximately 60 participants aged 30-60 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group trial lasting 8 weeks.
Participants will be assigned to receive either placebo, 150 mg GG, or 300 mg GG daily. Outcome measures will be assessed at baseline, week 4, and week 8 and include maximal strength (1RM bench press and leg press), fat-free mass, muscular endurance, aerobic capacity (VO2peak), and circulating biomarkers related to metabolism and health.
This study is a randomized, double-blind, placebo-controlled, parallel-group trial designed to examine the dose-response effects of geranylgeraniol (GG) supplementation on muscular strength, body composition, aerobic capacity, and physiological biomarkers in healthy, physically active adults.
Approximately 60 men and women aged 30-60 years will be recruited and randomized, stratified by sex, age, and baseline fat-free mass, to receive one of three interventions: placebo, 150 mg GG, or 300 mg GG daily for 8 weeks. All participants and study personnel will remain blinded to group allocation throughout the study.
Participants will complete a screening visit followed by testing visits at baseline (week 0), week 4, and week 8. Assessments will include maximal strength testing (1RM bench press and leg press), muscular endurance (repetitions to failure at a fixed percentage of 1RM), aerobic capacity (VO2peak via graded treadmill test), and body composition using a four-compartment model derived from dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance spectroscopy.
Venous blood samples will be collected to assess coenzyme Q10, sex steroid hormones, inflammatory markers, and clinical safety parameters including complete blood count, comprehensive metabolic panel, and lipid profile. Additional outcomes include mood and quality of life assessed via validated questionnaires (POMS and SF-36), dietary intake via 4-day food logs, and fecal samples for metabolomic analysis.
The primary endpoints are changes in maximal strength (1RM leg press and bench press) and fat-free mass from baseline to week 8. Secondary endpoints include changes in muscular endurance, aerobic capacity, body composition variables, biochemical markers, and patient-reported outcomes. Safety will be monitored throughout the study via clinical labs and adverse event reporting.
Lindenwood University is the lead sponsor of 29 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will ingest a placebo consisting of olive oil daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.
Dietary Supplement: Dietary Supplement - Placebo
Participants will ingest 150 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.
Dietary Supplement: Geranylgeraniol (150 mg)
Participants will ingest 300 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.
Dietary Supplement: Geranylgeraniol (300 mg)
Participants will ingest a placebo consisting of olive oil daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.
Participants will ingest 150 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.
Participants will ingest 300 mg of geranylgeraniol (GG) daily for 8 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.
Leg Press One-Repetition Maximum (1RM)
Maximal lower-body strength will be assessed as leg press one-repetition maximum (1RM), defined as the greatest load that can be lifted for one complete repetition using proper technique.
Time frame: Change from baseline (Week 0) to Week 8
Bench Press One-Repetition Maximum (1RM)
Maximal upper-body strength will be assessed as bench press one-repetition maximum (1RM), defined as the greatest load that can be lifted for one complete repetition using proper technique.
Time frame: Change from baseline (Week 0) to Week 8
Fat-Free Mass
Fat-free mass will be assessed using a four-compartment body composition model derived from dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance spectroscopy (BIS).
Time frame: Change from baseline (Week 0) to Week 8
Leg Press Muscular Endurance
Lower-body muscular endurance will be assessed as the number of repetitions completed to failure on the leg press using a load corresponding to 80% of the participant's baseline leg press 1RM.
Time frame: Change from baseline (Week 0) to Week 8
Bench Press Muscular Endurance
Upper-body muscular endurance will be assessed as the number of repetitions completed to failure on the bench press using a load corresponding to 80% of the participant's baseline bench press 1RM.
Time frame: Change from baseline (Week 0) to Week 8
Peak Oxygen Consumption (VO2peak)
Aerobic capacity will be assessed as peak oxygen consumption (VO2peak) during a graded treadmill exercise test.
Time frame: Change from baseline (Week 0) to Week 8
Fat Mass
Fat mass will be assessed using dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance spectroscopy (BIS).
Time frame: Change from baseline (Week 0) to Week 8
Percent Body Fat
Percent body fat will be assessed using dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance spectroscopy (BIS).
Time frame: Change from baseline (Week 0) to Week 8
Total Body Water
Total body water will be assessed using bioelectrical impedance spectroscopy (BIS).
Time frame: Change from baseline (Week 0) to Week 8
Intracellular Water
Intracellular water will be assessed using bioelectrical impedance spectroscopy (BIS).
Time frame: Change from baseline (Week 0) to Week 8
Extracellular Water
Extracellular water will be assessed using bioelectrical impedance spectroscopy (BIS).
Time frame: Change from baseline (Week 0) to Week 8
Plasma Coenzyme Q10 Concentration
Plasma coenzyme Q10 concentration will be assessed from venous blood samples.
Time frame: Change from baseline (Week 0) to Week 8
Serum Testosterone Concentration
Serum testosterone concentration will be assessed from venous blood samples.
Time frame: Change from baseline (Week 0) to Week 8
Serum Estrogen Concentration
Serum estrogen concentration will be assessed from venous blood samples.
Time frame: Change from baseline (Week 0) to Week 8
Serum Progesterone Concentration
Serum progesterone concentration will be assessed from venous blood samples.
Time frame: Change from baseline (Week 0) to Week 8
Profile of Mood States (POMS) Score
Mood state will be assessed using the Profile of Mood States (POMS) questionnaire.
Time frame: Change from baseline (Week 0) to Week 8
RAND SF-36 Score
Health-related quality of life will be assessed using the RAND SF-36 questionnaire.
Time frame: Change from baseline (Week 0) to Week 8
Fecal Metabolomic Profile
Fecal metabolomic outcomes will be assessed from self-collected stool samples.
Time frame: Change from baseline (Week 0) to Week 8
Resting Heart Rate
Resting heart rate will be assessed under standardized resting conditions.
Time frame: Change from baseline (Week 0) to Week 8
Resting Blood Pressure
Resting blood pressure will be assessed under standardized resting conditions.
Time frame: Change from baseline (Week 0) to Week 8
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Geranylgeraniol
Lindenwood University